Angiotensin-converting enzyme inhibition, intracellular Na+, and Na(+)-K+ pumping in cardiac myocytes

Am J Physiol. 1995 Feb;268(2 Pt 1):C366-75. doi: 10.1152/ajpcell.1995.268.2.C366.

Abstract

Angiotensin-converting enzyme (ACE) inhibitors can reduce cardiac mass in both clinical and experimental cardiac hypertrophy. Because cytoplasmic Na+ and pH have been implicated as regulators of cell growth, we examined the effect of treatment with an ACE inhibitor on intracellular Na+ activity (alpha iNa) and pH (pHi) in the heart. After treatment of rabbits with captopril for 8 days alpha iNa was reduced relative to controls (3.6 +/- 0.4, n = 8, vs. 8.2 +/- 0.4 mM, n = 9, P < 0.001), whereas pHi was unchanged. To account for the difference in alpha iNa we measured electrogenic Na(+)-K+ pump activity in single isolated myocytes. Treatment with captopril increased pump currents at near-physiological levels of intracellular Na+ but had no effect at near-saturating levels of Na+. A similar increase in Na(+)-K+ pump activity occurred in rabbits treated with another ACE inhibitor, enalapril, but not with the vasodilator, hydralazine. We speculate that a decrease in alpha iNa after treatment with captopril may contribute to the well-documented ability of ACE inhibitors to reduce cardiac mass.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Animals
  • Captopril / pharmacology
  • Enalapril / pharmacology
  • Heart / drug effects
  • Heart / physiology
  • Hydralazine / pharmacology
  • Hydrogen-Ion Concentration
  • Intracellular Membranes / metabolism*
  • Male
  • Myocardium / cytology
  • Myocardium / metabolism*
  • Rabbits
  • Sarcolemma / metabolism
  • Sodium / metabolism*
  • Sodium-Potassium-Exchanging ATPase / metabolism*
  • Time Factors

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Hydralazine
  • Enalapril
  • Captopril
  • Sodium
  • Sodium-Potassium-Exchanging ATPase